ArticleAllergy, asthma & immunology research2021
Risk Factors Predicting Severe Asthma Exacerbations in Adult Asthmatics: A Real-World Clinical Evidence.
Article in Allergy, asthma & immunology research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Uncontrolled Status, Disease Burden, and Associated Risk Factors Among Patients with Asthma Receiving Medium-to-High Dose ICS or ICS/LABA: A Retrospective Analysis.Advances in therapy · 2026Observational
- Article
- Real-world characterisation of severe asthma in Greece: results from the Greek Severe Asthma Registry.ERJ open research · 2026Article
- Eosinophil-Derived Neurotoxin Determinants and Reference Values in a Swedish Middle-Aged General Population.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2025Article
- Exploring the association between asthma and chronic comorbidities: impact on clinical outcomes.Frontiers in medicine · 2024Review
- Association of eosinophil-derived neurotoxin levels with asthma control status in patients with aspirin-exacerbated respiratory disease.Clinical and translational allergy · 2023Article
- Epithelial Autoantigen-Specific IgG Antibody Enhances Eosinophil Extracellular Trap Formation in Severe Asthma.Allergy, asthma & immunology research · 2022Article
- Effects of Asthma Medication Type on Asthma Exacerbation in a Real-World Setting.Yonsei medical journal · 2022Article
- A Comparison of the Effectiveness of Asthma Medications on Asthma Exacerbations in Real World National Cohort.Journal of asthma and allergy · 2022Article
- The influence of individual characteristics and non-respiratory diseases on blood eosinophil count.Clinical and translational allergy · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeMinimizing the future risk of asthma exacerbation (AE) is one of the main goals of asthma management. We investigated prognostic factors for risk of severe AE (SAE) in a real-world clinical setting.
methodsThis is an observational study evaluating subjects who were diagnosed with asthma and treated with anti-asthmatic medications from January 1995 to June 2018. Risk factors for SAE were analyzed in 2 treatment periods (during the initial 2 years and the following 3-10 years of treatment) using the big data of electronic medical records.
resultsIn this study, 5,058 adult asthmatics were enrolled; 1,335 (28.64%) experienced ≥ 1 SAE during the initial 2 years of treatment. Female sex, higher peripheral eosinophil/basophil counts, and lower levels of forced expiratory volume in 1 second (FEV1; %) were factors predicting the risk of SAEs (
conclusionsAsthmatics having risk factors for SAEs (female sex, higher peripheral eosinophil/basophil counts, and lower FEV1) should be strictly monitored to prevent future risk and improve clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.